Replies to post #458006 on Anavex Life Sciences Corp (AVXL)

[Steady_T]

I suggest you are using the term blinded in a way that is not its usual meaning.

As I read read your post I understand that what you mean is the company doesn't have the end of trial data to compare with the intake data at taken at the beginning of the OLE and therefore can not evaluate the intake data at this time.

Blinded generally is understood to mean that the data being taken by the CRO is not made available to the company until the end of the trial and that includes interim data from multiple sequential measures.

A minor quibble about word usage.